Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys

Virology

Volumn 283, Issue 1, 2001, Pages 59-68

  Cheng, Xing ^a   Zhou, Helen ^a   Tang, Roderick S ^a   Munoz, Mary G ^a   Jin, Hong ^a  

^a MEDIMMUNE   (United States)

Author keywords

African green monkeys; Chimeric RSV; Cotton rats; M2 2 deletion mutants; Recombinant respiratory syncytial virus; RSV vaccines

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CERCOPITHECIDAE; CHIMERA; CONTROLLED STUDY; LOWER RESPIRATORY TRACT; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; UPPER RESPIRATORY TRACT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0035946303     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0894     Document Type: Article

References (36)

1. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription
2. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test
3. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
4. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics
5. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene
6. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial viurs (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimapanzees
7. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates
8. Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: Homologous F and H proteins are required for virus viability
9. Low-temperature-grown RS virus in adult volunteers
10. Temperature-sensitive mutants of respiratory syncytial virus
11. Croup and pneumonia in human infants associated with a new strain of respiratory syncytial virus
12. Genetic alteration in a temperature-sensitive mutant of respiratory syncytial virus after replication in vivo
13. Isolation and characterization of a highly attenuated repiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus
14. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents
15. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV
16. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape
17. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo
18. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: Evaluation of the contributions of F and G glycoproteins to immunity
19. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: Extensive sequence divergence between antigenically related proteins
20. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine
21. Safety and antigenicity of temperature-sensitive (ts) mutant respiratory syncytial virus (RSV) in infants and children
22. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus
23. Respiratory syncytial virus
24. Isolation and characterization of further defective clone of a temperature-sensitive mutant (ts-1) of respiratory syncytial virus
25. Chimeric measles viruses with a foreign envelope
26. Monoclonal antibodies demonstrate heterogeneity in the G glycoprotein of prototype strains and clinical isolates of respiratory syncytial virus
27. Respiratory syncytial virus genetic and antigenic diversity
28. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1
29. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
30. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
31. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein
32. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees
33. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity
34. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates
35. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
36. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants